Trials / Completed
CompletedNCT00541996
Study Comparing Bioavailability of Oral Formulations of Vabicaserin
A Randomized, Open-Label, Single-Dose, 4-Period Crossover, Comparative Bioavailability Study of 3 Sustained- Release Formulations and an Immediate- Release Formulation of Vabicaserin (SCA-136) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vabicaserin |
Timeline
- Start date
- 2007-08-01
- Completion
- 2007-10-01
- First posted
- 2007-10-10
- Last updated
- 2007-12-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00541996. Inclusion in this directory is not an endorsement.